Abstract

Background

A prospective, randomized, double-blind, placebo-controlled trial of WC/rBS oral cholera vaccine was conducted in 502 U.S. college students attending summer educational programs in Mexico.

Methods

Two doses of vaccine (or placebo) were administered 10 days apart immediately after arrival in Mexico.

Results

The vaccine was free of significant adverse side effects. Anticholera toxin seroconversion was demonstrated in 86.7% of vaccinees compared to 8.2% of controls (p <.001). Postvaccination titers varied according to disease status (travelers' diarrhea) and enteropathogen isolated when disease developed. Protective efficacy (PE) against enterotoxigenic Escherichia coli (ETEC) diarrhea was 50% (95% Cl, 14–71 %), beginning 7 days after the second dose of WC/rBS. However, 74% of ETEC cases occurred within 7 days of the second dose, when no efficacy was demonstrated.

Conclusions

Vaccines employed to prevent travelers' diarrhea will likely need to be administered before arrival in a developing country to be predictably beneficial. An unexpected finding was that infection with LT-ETEC after primary oral cholera immunization appears to augment the antitoxin response to WC/rBS vaccine.

References

1
Okhuysen
PC
Ericsson
CD.
Travelers' diarrhea: prevention and treatment
.
Med Clin North Am
 
1992
;
76
:
1357
1373
.
2
Svennerholm
AM
Holmgren
J
Sack
DA.
Development of oral vaccines against enterotoxigenic Escherichia coli diarrhoea
.
Vaccine
 
1989
;
7
:
196
198
.
3
Levine
MM
Kaper
JB
Black
RE
Clements
ML.
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
.
Microbiol Rev
 
1983
;
47
:
510
550
.
4
Svennerholm
AM
Jertborn
M
Gothefors
L
Karim
AM
, et al.
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine
.
J Infect Dis
 
1984
;
149
:
884
893
.
5
Clemens
JD
Sack
DA
Harris
JR
Chakraborty
J.
et al.
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large scale field trial
.
J Infect Dis
 
1988
;
158
:
372
377
.
6
Peltola
H
Siitonen
A
Kyronseppa
H
Simula
I
, et al.
Prevention of travelers' diarrhoea by oral B-subunit/whole cell cholera vaccine
.
Lancet
 
1991
;
338
:
1285
1289
.
7
Jertborn
M
Svennerholm
AM
Holmgren
J.
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers
.
Vaccine
 
1992
;
10
:
130
132
.
8
Mathewson
JJ
Oberhelman
RA
DuPont
HL
de la Cabada
FJ
, et al.
Enteroadherent Escherichia coli as a cause of diarrhea among children in Mexico
.
J Clin Microbiol
 
1987
;
25
:
1917
1919
.
9
Orenstein
WA
Bernier
RH
Dondero
TJ
Hinman
AR
, et al.
Field evaluation of vaccine efficacy
.
Bull WHO
 
1985
;
63
:
1055
1068
.
10
Clemens
JD
Van Loon
F
Sack
DA
Chakraborty
J
, et al.
Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera
.
J Infect Dis
 
1991
;
163
:
1235
1242
.
11
Jertborn
M
Svennerholm
AM
Holmgren
J.
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease
.
J Clin Microbiol
 
1986
;
24
:
203
209
.
12
Holmgren
J
Svennerholm
AM
Gothefors
L
Jertborn
M
, et al.
Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination
.
Infect Immun
 
1988
;
56
:
230
233
.
13
Wenneras
C
Svennerholm
AM
Ahren
C
Czerkinsky
C.
Antibody secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine
.
Infect Immun
 
1992
;
60
:
2605
2611
.
Written informed consent was obtained from all patients. The study was approved by the Committee for the Protection of Human Subjects of the University of Texas and by the Walter Reed Army Institute of Research Human Use Review Committee and the Human Subjects Research Review Board.
Presented in part at the Third Conference on International Travel Medicine, Paris, France, April 1993.
This work was supported by DoD contract number DAMD 17-90-R-0048.